HDT Bio Pioneers a New Brain Cancer Treatment with McGill University's Canadian Program

HDT Bio Canada Inc. partners with McGill University and The Neuro to advance HDT-401, an investigational locally administered RNA immune activator, into Phase 1 clinical evaluation for glioblastoma in Canada